Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
The purpose of this study was to determine whether candesartan and its combination with probucol reduce restenosis after coronary stenting. A total of 132 patients who successfully underwent stenting were randomly assigned to a control group (n=45), a candesartan group (8 mg daily, n=43), or a candesartan plus probucol group (+ probucol 500 mg daily, n=44). No differences in late loss were observed between the control and candesartan groups. In the candesartan plus probucol group, late loss was significantly smaller than in the control and candesartan groups (p=0.003, 0.015). The restenosis rate was 27% in the control group, 26% in the candesartan group (p>0.99), and 11% in the candesartan plus probucol group (p=0.104 vs the control group and p=0.103 vs the candesartan group). Intravascular ultrasound revealed no differences in stent area among the 3 groups, and no differences in lumen area or in intimal hyperplasia area between the control and candesartan groups. However, the intimal hyperplasia area in the candesartan plus probucol group was significantly less than that in the control and candesartan groups (p<0.001, p<0.001). This study demonstrated that candesartan failed to inhibit the neointimal hyperplasia and although the combination treatment did reduce neointimal hyperplasia, it did not statistically reduce the restenosis rate.
Wakeyama
Takatoshi
T
The Division of Cardiology, Tokuyama Central Hospital, Japan. wakeyama@hotmail.com
Ogawa
Hiroshi
H
Iida
Hiroshi
H
Takaki
Akira
A
Iwami
Takahiro
T
Mochizuki
Mamoru
M
Tanaka
Takeo
T
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000473:pathology / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006965:Hyperplasia; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011341:Probucol / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011859:Radiography; D012307:Risk Factors; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology; D014463:Ultrasonography
D047228:Angiotensin II Type 1 Receptor Blockers; D000924:Anticholesteremic Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D011341:Probucol; C081643:candesartan